LA JOLLA, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company
focused on the development of precision medicines for oncology, today announced that Troy Wilson, Ph.D., J.D., President and Chief
Executive Officer, is scheduled to participate in two upcoming investor conferences.
- Jefferies 2017 Global Healthcare Conference, New York, June 6, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), company presentation
and overview
- JMP Securities Life Sciences Conference, New York, June 20, 2017 at 2:00 p.m. EDT (11:00 a.m. PDT), Small Molecule Oncology
Drugs: Challenges and Opportunities panel participant
A live audio webcast and replay of the presentation at the Jefferies conference will be available in the Investors section of
Kura Oncology's website at
www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where
there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from
treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in
multiple Phase 2 clinical trials. Kura’s pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 trial, and KO-539,
an inhibitor of the menin-MLL protein-protein interaction, currently in preclinical testing. For additional information about Kura
Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 robert.uhl@westwicke.com CORPORATE COMMUNICATIONS CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 mark@canalecomm.com
![Primary Logo](https://resource.globenewswire.com/Resource/Download/ee889fc4-c7c7-4823-8c42-aad89c075028?size=1)
![](http://www.globenewswire.com/newsroom/ti?ndecode=MTg0IzY4MTgzNjQ=)